Literature DB >> 10908824

Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer.

K D Stein1, P B Jacobsen, D M Hann, H Greenberg, G Lyman.   

Abstract

Hot flashes are among the most commonly reported symptoms among women who have completed treatment for breast cancer. Relatively little is known, however, about hot flashes among women while they are undergoing breast cancer treatment. The present study investigated the prevalence and severity of hot flashes of women during chemotherapy and radiotherapy for breast cancer. We also sought to identify the medical, demographic, and treatment correlates of hot flashes during treatment and to document the impact of hot flashes on quality of life. Seventy postmenopausal women with breast cancer completed a self-report questionnaire packet during chemotherapy and radiotherapy. Forty percent (n = 28) reported hot flashes during the week prior to assessment. Of the 28 women endorsing hot flashes, 25% (n = 7) rated them as severe, 39% (n = 11) rated them as moderate, and 36% (n = 10) rated them as mild. Women with hot flashes were significantly (p < 0.05) younger and reported significantly (p < 0.001) more fatigue, poorer sleep quality, and poorer physical health compared to women without hot flashes. Multivariate analyses revealed that, even after controlling for relevant medical, demographic, and treatment variables, the prevalence of hot flashes significantly (p < 0.05) predicted poorer sleep quality, more fatigue, and worse physical health. The results indicate that hot flashes are experienced by a sizable percentage of postmenopausal breast cancer patients as they undergo treatment. Hot flashes during cancer treatment appear to have a negative impact upon patient quality of life that may be due, in part, to fatigue and interference with sleep. Future research should seek to evaluate interventions to relieve hot flashes during breast cancer treatment as a means of improving patient quality of life.

Entities:  

Mesh:

Year:  2000        PMID: 10908824     DOI: 10.1016/s0885-3924(00)00142-1

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  28 in total

Review 1.  Sleep disturbance, inflammation and depression risk in cancer survivors.

Authors:  Michael R Irwin; Richard E Olmstead; Patricia A Ganz; Reina Haque
Journal:  Brain Behav Immun       Date:  2012-05-24       Impact factor: 7.217

2.  A comparison of disrupted sleep patterns in women with cancer-related fatigue and postmenopausal women without cancer.

Authors:  Horng-Shiuann Wu; Jean E Davis; Josna P Padiyar; Hossein Yarandi
Journal:  Eur J Oncol Nurs       Date:  2010-11-18       Impact factor: 2.398

3.  Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.

Authors:  G J van Londen; Heidi S Donovan; Ellen B Beckjord; Alexandra L Cardy; Dana H Bovbjerg; Nancy E Davidson; Jennifer Q Morse; Galen E Switzer; Irma M Verdonck-de Leeuw; Mary Amanda Dew
Journal:  Oncol Nurs Forum       Date:  2014-11-01       Impact factor: 2.172

Review 4.  Hormone replacement therapy for survivors of breast and endometrial cancer.

Authors:  Philip J DiSaia; Wendy R Brewster
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

5.  Hot flashes: the ongoing search for effective interventions.

Authors:  Kunal C Kadakia; Charles L Loprinzi; Debra L Barton
Journal:  Menopause       Date:  2012-07       Impact factor: 2.953

Review 6.  Filgrastim in patients with neutropenia: potential effects on quality of life.

Authors:  Gary H Lyman; Nicole M Kuderer
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions.

Authors:  Claire Johns; Susan M Seav; Sally A Dominick; Jessica R Gorman; Hongying Li; Loki Natarajan; Jun James Mao; H Irene Su
Journal:  Breast Cancer Res Treat       Date:  2016-03-26       Impact factor: 4.872

8.  Measuring hot flash phenomenonology using ambulatory prospective digital diaries.

Authors:  William I Fisher; Rebecca C Thurston
Journal:  Menopause       Date:  2016-11       Impact factor: 2.953

9.  Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction?

Authors:  Patricia A Ganz; J E Bower; L Kwan; S A Castellon; D H S Silverman; C Geist; E C Breen; M R Irwin; S W Cole
Journal:  Brain Behav Immun       Date:  2012-08-03       Impact factor: 7.217

Review 10.  Risk factors, pathophysiology, and treatment of hot flashes in cancer.

Authors:  William I Fisher; Aimee K Johnson; Gary R Elkins; Julie L Otte; Debra S Burns; Menggang Yu; Janet S Carpenter
Journal:  CA Cancer J Clin       Date:  2013-01-25       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.